In the summer of 2021, Q² Solutions opened a new state of the art, custom designed laboratory space, known as Q² Solutions Innovation Laboratories. Located on the new IQVIA Innovation Park Campus, in the heart of the dynamic Research Triangle Park in central North Carolina, this facility creates an innovative scientific community that includes multiple laboratory disciplines from service lines including Large Molecule Bioanalytical, Vaccines Center of Excellence, Genomics Center of Excellence and Translational Science and Innovation Laboratory (TSAIL).
With scientific thought leaders from anatomic pathology, flow cytometry, genomics, vaccine development, and large molecule bioanalytical services under one roof Q² Solutions is well poised to engineer solutions for sponsors that will support our mission to turn patients’ hope into the help they need.
Q² Solutions’ industry-leading genomic, molecular, and bioinformatics services provide customers with global testing to support clinical research and precision medicine, from discovery to late phase trials and companion diagnostic development. Q² Solutions works with clients, using a wide array of innovative technology platforms including next generation sequencing and targeted biomarker testing to ensure maximum efficiency and quality delivery for every study.
Our genomics and bioinformatics services provide DNA and RNA sequencing and other molecular testing to support drug discovery, translational medicine, clinical development, and precision medicine including companion diagnostics.
The following are some of the key features of our new genomics laboratory:
Our large molecule bioanalytical laboratory develops custom PK concentration, biomarker and anti-drug antibody/immunogenicity assays in support of all phases of drug development. Validation follows bioanalytical method validation guidance as applicable to ligand binding methodology. These assays are then put to action to support sample testing following a GLP/GCP quality system. Our laboratory also performs bioconjugation services and calculates statistical cut points in support of our sponsors.
The following are some of the key features of our new large molecule bioanalytical laboratory:
Our vaccines laboratory offers standard and custom services to support vaccine, infectious disease, and immunogenicity testing, as well as assay technology transfer and de novo assay development and validation. Balancing the promise of emerging technologies with the current needs of our clients, Q² Solutions’ anti-infective and vaccine development solutions include assay development, immunogenicity testing, genomic solutions, efficacy monitoring, project management and data management to meet your vaccine testing needs, whether it be product development or large-scale clinical trials. Q² Solutions’ offering includes an active global footprint, proven supply-chain and quality-management systems, and decades of specialized experience enabling us to be an invaluable and responsive partner at every stage of the vaccine development lifecycle.
The following are some of the key features of our new vaccines laboratory:
Q² Solutions’ state-of-the-art translational science and innovation laboratory (TSAIL) is designed to accelerate the drug development process with advanced laboratory capabilities spanning biomarker discovery through next generation vaccine, genomic and bioanalytical sciences, outside the regulatory confines of clinical trials. Q² Solutions' dedicated team of cross-disciplinary translational scientists work with clients to provide early access to technology-driven research and innovation as well as support early assay development to ensure better patient outcomes.
This previously unmet industry need will enable new technology evaluation and support early biomarker development to facilitate adoption of assays into clinical trials and advance the development of companion diagnostic tests to better impact patient outcomes.
The following are some of the key features of our new TSAIL laboratory: